{"id":401,"date":"2022-06-28T07:48:59","date_gmt":"2022-06-28T07:48:59","guid":{"rendered":"https:\/\/dianhuaminglu.com\/rd-pipeline\/"},"modified":"2022-09-06T12:15:13","modified_gmt":"2022-09-06T12:15:13","slug":"rd-pipeline","status":"publish","type":"page","link":"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/","title":{"rendered":"R&amp;D Pipeline"},"content":{"rendered":"\n<p>Focusing on <strong>innovation<\/strong> and <strong>patient accessibility<\/strong>, we have established a diversified and complementary R&amp;D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases.<\/p>\n\n<p>As we continue to enrich our pipeline and explore combination treatments, our fields of innovation R&amp;D has expanded from monoclonal antibodies to small molecule drugs, polypeptide drugs, antibody-drug conjugates (ADCs), bispecific antibody or multispecific antibody drugs, nucleotide drugs and etc. We will continue to further explore the next generation of innovative therapies for cancer and autoimmune diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Focusing on innovation and patient accessibility, we have established a diversified and complementary R&amp;D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases. As we continue [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/pipeline.php","meta":[],"yoast_head":"\n<title>R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"Focusing on innovation and patient accessibility, we have established a diversified and complementary R&amp;D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases. As we continue [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-06T12:15:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/\",\"url\":\"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/\",\"name\":\"R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"https:\/\/dianhuaminglu.com\/#website\"},\"datePublished\":\"2022-06-28T07:48:59+00:00\",\"dateModified\":\"2022-09-06T12:15:13+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dianhuaminglu.com\/#website\",\"url\":\"https:\/\/dianhuaminglu.com\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"https:\/\/dianhuaminglu.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dianhuaminglu.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dianhuaminglu.com\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"https:\/\/dianhuaminglu.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dianhuaminglu.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dianhuaminglu.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"https:\/\/dianhuaminglu.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"https:\/\/dianhuaminglu.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n","yoast_head_json":{"title":"R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269","og_description":"Focusing on innovation and patient accessibility, we have established a diversified and complementary R&amp;D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel antitumor targets drugs. Our products respond to a vast array of diseases, including cancer, autoimmune, metabolic, neurological, and infectious diseases. As we continue [&hellip;]","og_url":"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_modified_time":"2022-09-06T12:15:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/","url":"https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/","name":"R&amp;D Pipeline - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"https:\/\/dianhuaminglu.com\/#website"},"datePublished":"2022-06-28T07:48:59+00:00","dateModified":"2022-09-06T12:15:13+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dianhuaminglu.com\/en\/rd-pipeline\/"]}]},{"@type":"WebSite","@id":"https:\/\/dianhuaminglu.com\/#website","url":"https:\/\/dianhuaminglu.com\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"https:\/\/dianhuaminglu.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dianhuaminglu.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dianhuaminglu.com\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"https:\/\/dianhuaminglu.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dianhuaminglu.com\/#\/schema\/logo\/image\/","url":"https:\/\/dianhuaminglu.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"https:\/\/dianhuaminglu.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"https:\/\/dianhuaminglu.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/pages\/401"}],"collection":[{"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/comments?post=401"}],"version-history":[{"count":1,"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/pages\/401\/revisions"}],"predecessor-version":[{"id":402,"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/pages\/401\/revisions\/402"}],"wp:attachment":[{"href":"https:\/\/dianhuaminglu.com\/en\/wp-json\/wp\/v2\/media?parent=401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}